Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INVA
CUSIP88338T10
Phone650-238-9600
Debt
Debt-to-Equity Ratio-3.13
Current Ratio26.39
Quick Ratio26.39
Price-To-Earnings
Trailing P/E Ratio11.95
Forward P/E Ratio7.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.22 million
Price / Sales6.56
Cash Flow$1.5108 per share
Price / Cash9.26
Book Value($2.38) per share
Price / Book-5.88
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$134.14 million
Net Margins70.01%
Return on Equity-83.69%
Return on Assets50.79%
Miscellaneous
Employees12
Outstanding Shares101,820,000
Market Cap$1.41 billion
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) announced its earnings results on Thursday, July, 26th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.55 by $0.06. The biotechnology company earned $67.09 million during the quarter, compared to analyst estimates of $68.50 million. Innoviva had a net margin of 70.01% and a negative return on equity of 83.69%. Innoviva's revenue was up 14.6% on a year-over-year basis. During the same quarter last year, the business earned $0.30 earnings per share. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
6 analysts have issued 12 month target prices for Innoviva's shares. Their predictions range from $8.00 to $16.00. On average, they expect Innoviva's stock price to reach $13.20 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View Analyst Price Targets for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Innoviva.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP) and Horizon Pharma (HZNP).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Eric d'Esparbes, Interim Principal Exec. Officer, Sr. VP & CFO (Age 50)
- Dr. Theodore J. Witek Jr., Sr. VP & Chief Scientific Officer (Age 60)
- Mr. George B. Abercrombie M.B.A., R.Ph., RPh, MBA, Sr. VP & Chief Commercial Officer (Age 63)
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
Has Innoviva been receiving favorable news coverage?
Media coverage about INVA stock has been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innoviva earned a news and rumor sentiment score of 0.08 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Innoviva.
Who are Innoviva's major shareholders?
Innoviva's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.41%), Renaissance Technologies LLC (3.33%), FMR LLC (2.64%), Bank of America Corp DE (2.03%), Point72 Asset Management L.P. (1.89%) and Dimensional Fund Advisors LP (1.87%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Which major investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, American Century Companies Inc., PNC Financial Services Group Inc., Sawgrass Asset Management LLC, Victory Capital Management Inc., Millennium Management LLC, Schroder Investment Management Group and GSA Capital Partners LLP. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.
Which major investors are buying Innoviva stock?
INVA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Renaissance Technologies LLC, LSV Asset Management, BlackRock Inc., Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Bank of America Corp DE and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $13.99.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.41 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
